Payer+Provider's Health System Review
July 11, 2025
The FDA is failing rare disease patients. I’m one of them. I’ve been on elamipretide for three years now. It is the only treatment that has made a meaningful difference in my life with primary mitochondrial myopathy—a degenerative genetic c…